Prostate Cancer

Study: MetaMouse model predicts recurrence in human prostate cancer patients

Published in Gene Therapy Weekly, June 10th, 2004

A recent article in the Journal of Clinical Investigation by Gennadi Glinsky, et al., describes how scientists from AntiCancer, Inc., and the Sidney Kimmel Cancer Center have used AntiCancer's MetaMouse model of metastatic human prostate cancer to determine genetic signatures, which predict whether patients would have recurrence of prostate cancer.

Existing procedures for prediction of recurrence of prostate cancer, including blood tests such as the prostate specific antigen test and other standard pathological examinations that have been used for decades, have limited prognostic capability. According to the company, AntiCancer's clinically relevant MetaMouse...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry